title: New levodopa therapeutic strategies.
abstract: During its almost half-century of use for treating Parkinson's disease, levodopa therapy has permitted most patients to reverse much of this disorder's symptomatology. However, the full range of its therapeutic properties is not completely understood, as levodopa is showing itself to be more than just a metabolic intermediate for dopamine synthesis. Improving the constancy of drug delivery is the next frontier for enhancing therapeutic options with levodopa. Because conventional immediate-release carbidopa-levodopa tablets yield such variable pharmacokinetic profiles (as do other marketed products attempting to extend levodopa effect), improved formulations are greatly needed by patients experiencing motor fluctuations. Products under development or recently released in the U.S. include intestinal infusion, sustained-release microtablets, gastric-retentive formulations, a levodopa pro-drug, and methods for delivery of the drug by inhalation or subcutaneous infusion.
authors.affiliation: Department of Neurology, Henry Ford Hospital and Wayne State University School of Medicine, 6777 West Maple Road, West Bloomfield, MI 48322, USA. Electronic address: plewitt1@hfhs.org.
authors.forename: Peter A
authors.initials: PA
authors.lastname: LeWitt
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004338:Drug Combinations; D016503:Drug Delivery Systems / Q000639:trends*; D006801:Humans; D007263:Infusions, Parenteral; D055104:Infusions, Subcutaneous; D007980:Levodopa / Q000008:administration & dosage* / Q000493:pharmacokinetics; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D000978:Antiparkinson Agents; D004338:Drug Combinations; D007980:Levodopa
keywords: Drug delivery; Levodopa; Parkinson disease; Pharmacotherapy